Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
721actual
Sites
13
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-29 | actual | When the study began enrolling |
| Primary completion | 2025-06-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hereditary Transthyretin Amyloidosis
- Carpal Tunnel Syndrome
- Polyneuropathy
- Amyloidosis
Primary outcome
what the primary-completion date above is the date OFTo define the prevalence of ATTR PN in patients diagnosed with CTS and having bilateral involvement in routine clinical practice in the Russian Federation.
measured Up to 12 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed